Transcenta-B Proposes Appointment of Xu Hansen as Non-Executive Director

Stock News
06/04

The board of Transcenta Holding Limited - B (ASX: 06628) has announced a series of proposed changes to its composition and committee memberships.

It is recommended that Dr. Hansen Xu be appointed as a Non-Executive Director and that Dr. Jun Bao be appointed as an Independent Non-Executive Director. These appointments are subject to approval by the company's shareholders at the Annual General Meeting scheduled for June 30, 2026.

Concurrently, Dr. Kumar Srinivasan and Mr. Zhihua Zhang have tendered their resignations as Independent Non-Executive Directors to dedicate more time to other commitments. Their resignations will become effective upon the appointments of Dr. Xu and Dr. Bao.

Following their respective departures, Dr. Srinivasan will step down from his roles as Chairman of the Remuneration Committee and as a member of the Nomination Committee. Mr. Zhang will relinquish his positions as Chairman of the Nomination Committee, and as a member of both the Audit Committee and the Remuneration Committee.

Changes to the composition of the Audit, Remuneration, and Nomination Committees will also take effect once the new directors are appointed. Under the proposed changes, Dr. Jun Bao will join the Remuneration, Audit, and Nomination Committees. Ms. Wei Chen will be appointed as the Chairman of the Remuneration Committee. Dr. Hansen Xu will become a member of the Remuneration Committee, and Dr. Xueming Qian will be appointed as the Chairman of the Nomination Committee.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10